Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT04595266	TitleQuimioembolización (Lifepearls-Irinotecan) en pacientes con cáncer colorrectal y enfermedad metastásica	Fase Fase 2	Date Added 2020-10-20	Ubicación España	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04589845	TitleEstudio de la plataforma TAPISTRY (Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You)	Fase Fase 2	Date Added 2020-10-19	Ubicación Alabama, United States Arizona, United States California, United States Colorado, United States Delaware, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Maine, United States Maryland, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Australia Bélgica Brasil Canadá China Dinamarca Francia Alemania Hong Kong Israel Italia Japón Corea, República de Nueva Zelanda Polonia Portugal Puerto Rico Singapur Sudáfrica España Suiza Taiwán Reino Unido	Prior IO Allowed No	CRC-directed No	Status Reclutamiento	Drogas Alectinib, Atezolizumab, Belvarafenib, Entrectinib, Idasanutlin, Inavolisib, Ipatasertib, Pralsetinib, Trastuzumab emtansine	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04591431	TitleThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy	Fase Fase 2	Date Added 2020-10-19	Ubicación Italia	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib	Etiquetas MSS/ MMRp
NCT ID NCT04575922	TitleNivolumab+Ipilimumab+RT in MSS mCRC	Fase Fase 2	Date Added 2020-10-05	Ubicación Massachusetts, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Ipilimumab, Nivolumab	Etiquetas MSS/ MMRp
NCT ID NCT04550897	TitleA Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients	Fase Fase 1	Date Added 2020-09-16	Ubicación Noruega	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas BM7PE	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04535024	TitleThe Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer	Fase Fase 2	Date Added 2020-09-01	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Sintilimab	Etiquetas MSS/ MMRp
NCT ID NCT04483219	TitleTyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.	Fase Fase 2	Date Added 2020-07-23	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Unknown status	Drogas TKI ± anti-PD-1 antibody	Etiquetas MSS/ MMRp
NCT ID NCT04444622	TitleImmunotherapy for Third Line Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2020-06-23	Ubicación Florida, United States Michigan, United States New Jersey, United States New York, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT04432857	TitleAN0025 and Pembrolizumab Combination in Advanced Solid Tumors	Fase Fase 1	Date Added 2020-06-16	Ubicación Missouri, United States Texas, United States Utah, United States Virginia, United States Francia	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas AN0025, Pembrolizumab	Etiquetas MSS/ MMRp
NCT ID NCT04426669	TitleEstudio de cánceres gastrointestinales metastásicos tratados con linfocitos infiltrantes tumorales en los que se inhibe el gen que codifica el punto de control inmunitario intracelular CISH mediante ingeniería genética CRISPR.	Fase Phase 1, Phase 2	Date Added 2020-06-11	Ubicación Minnesota, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL)	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 151 to 160 of 299 entries